Antisense extracellular signal-regulated kinase-2 gene therapy inhibits platelet-derived growth factor-induced proliferation, migration and transforming growth factor-β1 expression in vascular smooth muscle cells and attenuates transplant vasculopathy

Transplant International

Volumn 21, Issue 1, 2008, Pages 30-38

  Chen, Xi Lin ^a   Chen, Zhi Shui ^a   Ding, Zhao ^a   Dong, Chong ^a   Guo, Hui ^a   Gong, Nian Qiao ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Extracellular signal regulated kinase; Gene therapy; Migration; Platelet derived growth factor; Proliferation; Vascular smooth muscle cell

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTISENSE THERAPY; AORTA GRAFT; ARTICLE; ATTENUATION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVITY; EX VIVO GENE TRANSFER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANGIOGENESIS INDUCING AGENTS; ANIMALS; AORTA; AORTITIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENETIC VECTORS; GRAFT REJECTION; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MUSCLE, SMOOTH, VASCULAR; PLATELET-DERIVED GROWTH FACTOR; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; TRANSFORMING GROWTH FACTORS;

EID: 36649001397     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00570.x     Document Type: Article

References (43)

1. Légaré JF, Issekutz T, Lee TD, Hirsch G. CD8+ T lymphocytes mediate destruction of the vascular media in a model of chronic rejection. Am J Pathol 2000 157 : 859.
2. Russell ME. Cardiac allograft vasculopathy - a changing perspective. Z Kardiol 2000 89 : IX/6.
3. Avery RK. Cardiac-allograft vasculopathy. N Engl J Med 2003 349 : 829.
4. Deuel TF, Huang JS. Platelet-derived growth factor. Structure, function, and roles in normal and transformed cells. J Clin Invest 1984 74 : 669.
5. Sterpetti AV, Cucina A, Lepidi S, et al. Progression and regression of myointimal hyperplasia in experimental vein grafts depends on platelet-derived growth factor and basic fibroblastic growth factor production. J Vasc Surg 1996 23 : 568.
6. Lemström KB, Koskinen PK. Expression and localization of platelet-derived growth factor ligand and receptor protein during acute and chronic rejection of rat cardiac allografts. Circulation 1997 96 : 1240.
7. 1 regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem 1991 266 : 9419.
8. Zegarska J, Paczek L, Pawlowska M, et al. Increased mRNA expression of transforming growth factor beta in the arterial wall of chronically rejected renal allografts in humans. Transplant Proc 2006 38 : 115.
9. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001 81 : 807.
10. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995 270 : 1326.
11. Brunet A, Roux D, Lenormand P, Dowd S, Keyse S, Pouysségur J. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J 1999 18 : 664.
12. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999 79 : 1283.
13. Zhan Y, Kim S, Izumi Y, et al. Role of JNK, p38, and ERK in platelet-derived growth factor-induced vascular proliferation, migration, and gene expression. Arterioscler Thromb Vasc Biol 2003 23 : 795.
14. Bost F, Aouadi M, Caron L, et al. The extracellular signal-regulated kinase isoform ERK1 is specifically required for in vitro and in vivo adipogenesis. Diabetes 2005 54 : 402.
15. Vantaggiato C, Formentini I, Bondanza A, Bonini C, Naldini L, Brambilla R. ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. J Biol 2006 5 : 14.
16. 1 cell cycle progression and cancer. Cancer Sci 2006 97 : 697.
17. Mizuguchi H, Kay MA. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther 1999 10 : 2013.
18. Majack RA. Beta-type transforming growth factor specifies organizational behavior in vascular smooth muscle cell cultures. J Cell Biol 1987 105 : 465.
19. Huang J, Kontos CD. Inhibition of vascular smooth muscle cell proliferation, migration, and survival by the tumor suppressor protein PTEN. Arterioscler Thromb Vasc Biol 2002 22 : 745.
20. Yuan R, Flurkey K, Van R, et al. Altered growth characteristics of skin fibroblasts from wild-derived mice, and genetic loci regulating fibroblast clone size. Aging Cell 2006 5 : 203.
21. Saito S, Frank GD, Motley ED, et al. Metalloprotease inhibitor blocks angiotensin II-induced migration through inhibition of epidermal growth factor receptor transactivation. Biochem Biophys Res Commun 2002 294 : 1023.
22. Libby P, Pober JS. Chronic rejection. Immunity 2001 14 : 387.
23. Atkinson C, Horsley J, Rhind-Tutt S, et al. Neointimal smooth muscle cells in human cardiac allograft coronary artery vasculopathy are of donor origin. J Heart Lung Transplant 2004 23 : 427.
24. Park J, Ha H, Seo J, et al. Mycophenolic acid inhibits platelet-derived growth factor-induced reactive oxygen species and mitogen-activated protein kinase activation in rat vascular smooth muscle cells. Am J Transplant 2004 4 : 1982.
25. Alpers CE, Davis CL, Barr D. Identification of PDGF-A and B chains in human renal vascular rejection. Am J Pathol 1996 148 : 439.
26. Hayry P, Mennander A, Raisanen SA, et al. Pathophysiology of vascular wall changes in chronic allograft rejection. Transplant Rev 1993 7 : 1.
27. Savikko J, Taskinen E, Von Willebrand E. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. Transplantation 2003 75 : 1147.
28. Cartel NJ, Liu J. PDGF-BB-mediated activation of p42 (MAPK) is independent of PDGF beta-receptor tyrosine phosphorylation. Am J Physiol Lung Cell Mol Physiol 2001 281 : L786.
29. Heldin CH. Simultaneous induction of stimulatory and inhibitory signals by PDGF. FEBS Lett 1997 410 : 17.
30. Moore DJ, Markmann JF, Deng S. Avenues for immunomodulation and graft protection by gene therapy in transplantation. Transpl Int 2006 19 : 435.
31. Izumi Y, Kim S, Namba M, et al. Gene transfer of dominant negative mutants of extracellular signal-regulated kinase and c-Jun NH2-terminal kinase prevents neointimal formation in balloon-injured rat artery. Circ Res 2001 88 : 1120.
32. Gong N, Zhang W, Li G, Guo H, Ye Q. MAPK cascade pathway and anti-stress response of hepatocyte after live transplantation. Chin J Organ Transplant 2002 23 : 288 (in Chinese).
33. Li GX, Gong NQ, Ye QF, Guo H. Different effects of several signal pathway after liver transplantation. Zhonghua Gan Zang Bing Za Zhi 2003 11 : 742 (in Chinese).
34. Dong C, Gong N, Chen Z, et al. Antisense ERK1/2 oligodeoxynucleotide gene therapy attenuates graft arteriosclerosis of aortic transplant in a rat model. Transplant Proc 2006 38 : 3304.
35. Gong N, Dong C, Chen Z, et al. Adenovirus-mediated antisense-ERK2 gene therapy attenuates chronic allograft nephropathy. Transplant Proc 2006 38 : 3228.
36. Hauck CR, Hsia DA, Schlaepfer DD. Focal adhesion kinase facilitates platelet-derived growth factor-BB-stimulated ERK2 activation required for chemotaxis migration of vascular smooth muscle cells. J Biol Chem 2000 275 : 41092.
37. Zhan Y, Kim S, Yasumoto H, Namba M, Miyazaki Hitoshi, Iwao H. Effects of dominant-negative c-Jun on platelet-derived growth factor-induced vascular smooth muscle cell proliferation. Arterioscler Thromb Vasc Biol 2002 22 : 82.
38. Li J, Huang SL, Guo Z. Platelet-derived growth factor stimulated vascular smooth muscle cell proliferation and its molecular mechanism. Acta Pharmacol Sin 2000 21 : 340.
39. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003 113 : 685.
40. Waller JR, Nicholson ML. Molecular mechanisms of renal allograft fibrosis. Br J Surg 2001 88 : 1429.
41. Cohen MM. TGF-β/Smad signaling system and its pathologic correlates. Am J Med Gene 2003 116A : 1.
42. Gong N, Chen X, Ding Z, et al. Chronic allograft nephropathy: the mechanisms and strategies. Hong Kong J Nephrol 2007 9 : 58.
43. Zhang YL, Dong C. MAP kinases in immune responses. Cell Mol Immunol 2005 2 : 20.